What are the comparative effects of metformin and myo-inositol on clinical and metabolic features in women with PCOS?
Myo-Inositol, a randomized trial (Gynecol Endocrinol 2016, PMID 27808588) — metformin and myo-inositol are both useful in women with PCOS for lowering BMI, ameliorating insulin sensitivity, and improving menstrual cycles, with no significant differences between the two treatments. Scope: over 6 months, and the abstract states no limitations.
Source: Gynecol Endocrinol 2016, PMID 27808588 ↗ · Research map · How Magellan grades evidence · evidence confidence: low
Gynecol Endocrinol · 2016 · PMID 27808588 · DOI 10.1080/09513590.2016.1236078
Metformin and myo-inositol similarly improve insulin sensitivity, BMI, and menstrual cycles in women with PCOS.
The question
What are the comparative effects of metformin and myo-inositol on clinical and metabolic features in women with PCOS?
What they tested
Insulin-sensitizer agents like metformin and inositols improve endocrine and metabolic aspects of PCOS, and this study aims to compare their effects.
How they did it
Fifty women with PCOS, insulin resistance (HOMA-IR >2.5) and/or hyperinsulinemia, were randomized to receive either metformin (1500 mg/day) or myo-inositol (4 g/day) for 6 months. Researchers evaluated insulin secretion, BMI, menstrual cycle length, acne, and hirsutism at baseline and after treatment. Insulin resistance was defined as HOMA-IR >2.5, and hyperinsulinemia was defined by AUC for insulin after a glucose load above the laboratory's normal cutoff.
What they found
Both treatment groups showed similar improvements. Insulin sensitivity improved in both groups. BMI significantly decreased, and the menstrual cycle normalized in approximately 50% of the women. No significant changes were observed in acne or hirsutism.
What it means
Metformin and myo-inositol are both useful in women with PCOS for lowering BMI, ameliorating insulin sensitivity, and improving menstrual cycles, with no significant differences between the two treatments.
Limitations
The abstract does not explicitly state any limitations of the study.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Title | Comparison of two insulin sensitizers, metformin and myo-inositol, in women with PCOS |
|---|---|
| Journal | Gynecol Endocrinol |
| Year | 2016 |
| PMID | 27808588 ↗ |
| DOI | 10.1080/09513590.2016.1236078 ↗ |
| Topic | Metabolic health, glucose & body composition |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Myo-Inositol
In randomized trials and meta-analyses, myo-inositol (often combined with D-chiro-inositol) has been associated with improved insulin sensitivity—lower fasting insulin and HOMA-IR—restoration of menstrual regularity and ovulation in PCOS, and a reduced incidence of gestational diabetes (a Cochrane review found…
Myo-inositol is a naturally occurring sugar-like compound (a cyclitol, the most abundant of nine…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). What are the comparative effects of metformin and myo-inositol on clinical and metabolic features in women with PCOS? [Plain-English summary of Gynecol Endocrinol 2016, PMID 27808588, DOI 10.1080/09513590.2016.1236078]. Magellan Longevity. https://magellanlongevity.com/study/d27808588.html@misc{magellan_d27808588,
title = {What are the comparative effects of metformin and myo-inositol on clinical and metabolic features in women with PCOS?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d27808588.html}},
note = {Plain-English summary of PubMed PMID 27808588; DOI 10.1080/09513590.2016.1236078; Gynecol Endocrinol 2016. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d27808588.htmlRelated studies in the Magellan library
- A randomized controlled trial comparing myoinositol with metformin versus metformin…Clin Endocrinol (Oxf) · 2023 · PMID 37265016
- What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS)…Reprod Biol Endocrinol · 2023 · PMID 36703143
- Sulforaphane reduces hepatic glucose production and improves glucose control in patients with…Sci Transl Med · 2017 · PMID 28615356
- Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and…Mechanisms of Ageing and Development · 2015 · PMID 25824609
- What are the fundamental mechanisms by which tea consumption reduces body weight, alleviates…Mol Nutr Food Res · 2015 · PMID 26577614
- Does carnosine supplementation improve cardiometabolic health and cognitive function in…BMJ Open · 2017 · PMID 28864708
All 22 Magellan summaries on metabolic health, glucose & body composition →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →